What contraception precautions apply to females and males during and after treatment with Tivdak (tisotumab vedotin)?

Before Tivdak (tisotumab vedotin), verify pregnancy status in females of childbearing potential; effective contraception is advised during treatment and for at least 2 months after stopping for these females, and during treatment and for at least 4 months after the last dose for males with female partners of reproductive potential.